Tsuji A, Asano T, Suzuki S, Aoyagi T, Hayakawa M, Nakamura H
Department of Urology, National Defense Medical College, Tokorozawa, Japan.
Nihon Jinzo Gakkai Shi. 1996 May;38(5):198-201.
We investigated the effect of herbimycin A on the monolayer growth of 4 human renal cell carcinoma (RCC) cell lines and a normal renal tubular cell line (RTC 13) using MTT [3-(4,5-dimethylthiszol-2,5-diphenyl tetrazolium bromide)] assay. Herbimycin A induced remarkable growth inhibition in each RCC cell line tested, without any morphological changes of the cells. At the concentration of 500 ng/ml, herbimycin A caused more than a 30% growth inhibition in all RCC cells (p < 0.005 vs RTC 13), while less than 7% growth inhibition was observed in RTC 13 at the same herbimycin A concentration. The cell cycle was estimated by analysing DNA (deoxyribonucleic acid) content using a FACS. A DNA histogram of RCC cells treated at herbimycin A showed a block in the cell cycle at the S and G2M phases. However, little effect by herbimycin A on RTC 13 cells was observed. Our results suggest that protein tyrosine kinases inhibitors, like herbimycin A, may offer a new treatment option for RCC patients.
我们使用MTT [3-(4,5-二甲基噻唑-2,5-二苯基溴化四氮唑)] 分析法，研究了赫伯霉素A对4种人肾细胞癌（RCC）细胞系和1种正常肾小管细胞系（RTC 13）单层生长的影响。赫伯霉素A对每种测试的RCC细胞系均诱导出显著的生长抑制，且细胞无任何形态变化。在500 ng/ml的浓度下，赫伯霉素A对所有RCC细胞均造成超过30%的生长抑制（与RTC 13相比，p < 0.005），而在相同赫伯霉素A浓度下，RTC 13的生长抑制率不到7%。通过使用流式细胞仪分析DNA（脱氧核糖核酸）含量来估计细胞周期。经赫伯霉素A处理的RCC细胞的DNA直方图显示，细胞周期在S期和G2M期受阻。然而，未观察到赫伯霉素A对RTC 13细胞有明显影响。我们的结果表明，像赫伯霉素A这样的蛋白酪氨酸激酶抑制剂可能为RCC患者提供一种新的治疗选择。
